http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2036413-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8de074c855f78a1266b1b4b3620287e
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
filingDate 1991-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5545d28cb1780a2ca3296c91e8de0e27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3a4bb2974943118da52f58e1fe1ee16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f20d07a89732be6e432148620313122d
publicationDate 1991-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2036413-A1
titleOfInvention Hiv protease inhibitors
abstract Disclosed herein are compounds of the general formula X-A-B-Y wherein X is R1OC(O), R1NHC(O) or R1C(O) wherein R1 is, for example, alkyl, optionally substituted phenyl or optionally substituted benzyl, A is a non-peptide linking unit, e.g. statyl or Phe~[CH2NH]Leu, B is an amino acid residue of glutamic acid or a related derivative thereof, and Y is alkoxy, cycloalkoxy, a substituted alkoxy or a substituted amino group, e.g. cycloalkyl-alkoxy, aralkoxy, alkylamino, (cycloalkyl)alkylamino or aralkylamino. The compounds inhibit the activity of human immunodeficiency virus (HIV) protease and interfere with HIV induced cytopathogenic effects in human cells. These properties render the compounds useful for combating HIV infections.
priorityDate 1990-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID12721
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID26383
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415713912
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100862683
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556475
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID12721
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487901

Total number of triples: 42.